Telomir Pharmaceuticals announced that its lead compound, Telomir-1, significantly reduces oxidative stress in human retinal cell lines, showing promise for treating age-related macular degeneration (AMD). The study found that Telomir-1 effectively mitigates damage caused by copper and iron exposure, leading to further evaluation in AMD disease models.